Skip to content
DataLookout
Menu

NCT06555068

A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 31 words
    • Interventions modified
    • Trial arms changed: 9 → 13
    • Study title expanded, about 8 words
  2. Notable Primary completion date: Dec 2025 to Dec 2027v6 Show 5 more changesShow less
    • Eligibility criteria expanded, about 64 words
    • Study completion date: Aug 2026 to Aug 2028
    • Interventions: HRS-6209 in Combination with Fulvestrant (Drug), HRS-6209 in Combination with HRS-1358 (Drug), HRS-6209 in Combination with HRS-1358… to HRS-6209 in Combination with Fulvestrant (Drug), HRS-6209 in Combination with HRS-1358 (Drug), HRS-6209 in Combination with HRS-1358…
    • Secondary endpoints: details revised at 8 of 18 entries
    • Study arms: 5 to 9
  3. Notable Eligibility criteria expanded, about 5 wordsv4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2024 to Aug 12, 2024
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

DLT (dose-limiting toxicity)-Stage I (dose exploration)
Timeframe: 28 days after the first dose
MTD (maximum tolerated dose) -Stage I (dose exploration)
Timeframe: 28 days after the first dose
RP2D (recommended phase II dose) -Stage I (dose exploration)
Timeframe: 28 days after the first dose
(Serious) AEs-Stage I (dose exploration)
Timeframe: every week in Cycle 1 (28 days after the first dose), every 2 weeks in Cycle 2 (28 days after the second dose), every 4 weeks from Cycle 3 and thereafter (28 days after each dose), lasting about one year
ORR ( objective response rate )-Stage II (efficacy expansion)
Timeframe: every 8 weeks lasting about one year

Secondary (18)

Cmax, ss (Stage I)
Tmax, ss (Stage I)
Cmin, ss(Stage I)
AUCss (Stage I)
ORR (objective response rate) (Stage I)
Show 13 moreShow less
BOR (best overall response) (Stage I)
DoR (duration of response) (Stage I)
CBR (clinical benefit rate) (Stage I)
PFS (progression-free survival) (Stage I)
(Serious) AEs (Stage II)
Cmax, ss (Stage II)
Tmax, ss (Stage II)
Cmin, ss(Stage II)
AUCss (Stage II)
BOR (best overall response) (Stage II)
DoR (duration of response) (Stage II)
CBR (clinical benefit rate) (Stage II)
PFS (progression-free survival) (Stage II)

Arms and interventions

Treatment group A: HRS-6209 in Combination with FulvestrantExperimental
Treatment group E: HRS-6209 in Combination with HRS-1358Experimental
Treatment group B:HRS-6209 in Combination with LetrozoleExperimental
Treatment group C:HRS-6209 in Combination with HRS-8080Experimental
Treatment group D:HRS-6209 in Combination with HRS-8080Experimental
Treatment group F: HRS-6209 in Combination with HRS-1358Experimental
Treatment group G:HRS-6209 in Combination with HRS-9813 and LetrozoleExperimental
Treatment group H:HRS-6209 in Combination with HRS-9813 and HRS-8080Experimental
Treatment group I:HRS-6209 in Combination with HRS-9813 and HRS-8080Experimental
Treatment group PART3-AExperimental
Treatment group PART3-BExperimental
Treatment group PART3-C-Experimental
Treatment group PART3-DExperimental

Drugs: HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole, HRS-6209 in Combination with HRS-8080, HRS-6209 in Combination with HRS-9813 and Letrozole, HRS-6209 in Combination with HRS-9813 and HRS-8080, HRS-6209 in Combination with letrozole and trastuzumab, HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab, HRS-6209 in Combination HRS-4508 and letrozole, HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China